How do partners find out about the risk of Huntington's disease in couple relationships?

Forrest Keenan K, Simpson SA, Miedzybrodzka Z, Alexander DA, Semper J.

J Genet Couns. 2013 Jun;22(3):336-44. doi: 10.1007/s10897-012-9562-2.

Deficits in a Simple Visual Go/No-go Discrimination Task in Two Mouse Models of Huntington's Disease.

Oakeshott S, Farrar A, Port R, Cummins-Sutphen J, Berger J, Watson-Johnson J, Ramboz S, Howland D, Brunner D.

PLoS Curr. 2013 Nov 7;5. pii: ecurrents.hd.fe74c94bdd446a0470f6f905a30b5dd1. doi: 10.1371/currents.hd.fe74c94bdd446a0470f6f905a30b5dd1.

The Addenbrooke's Cognitive Examination-Revised accurately detects cognitive decline in Huntington's disease.

Begeti F, Tan AY, Cummins GA, Collins LM, Guzman NV, Mason SL, Barker RA.

J Neurol. 2013 Nov;260(11):2777-85. doi: 10.1007/s00415-013-7061-5.

Qualitative study on the placement of Huntington disease patients in a psychiatric hospital: perceptions of Maltese nurses.

Scerri J, Cassar R.

Nurs Health Sci. 2013 Dec;15(4):444-8. doi: 10.1111/nhs.12053.

The functional implications of motor, cognitive, psychiatric, and social problem-solving states in Huntington's disease.

Van Liew C, Gluhm S, Goldstein J, Cronan TA, Corey-Bloom J.

Psychiatry. 2013 Winter;76(4):323-35. doi: 10.1521/psyc.2013.76.4.323.

The challenge of juvenile Huntington disease: to test or not to test.

Koutsis G, Karadima G, Kladi A, Panas M.

Neurology. 2013 Mar 12;80(11):990-6. doi: 10.1212/WNL.0b013e31828727fa.

Functional and connectivity changes during working memory in Huntington's disease: 18 month longitudinal data from the IMAGE-HD study.

Georgiou-Karistianis N, Poudel GR, Domínguez D JF, Langmaid R, Gray MA, Churchyard A, Chua P, Borowsky B, Egan GF, Stout JC.

Brain Cogn. 2013 Oct;83(1):80-91. doi: 10.1016/j.bandc.2013.07.004.

Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data.

Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, Borowsky B, Landwehrmeyer B, Frost C, Johnson H, Craufurd D, Reilmann R, Stout JC, Langbehn DR; TRACK-HD Investigators..

Lancet Neurol. 2013 Jul;12(7):637-49. doi: 10.1016/S1474-4422(13)70088-7.

Neurodegenerative disease: altered DNA methylation and RNA splicing could be key mechanisms in Huntington disease.

Wood H.

Nat Rev Neurol. 2013 Mar;9(3):119. doi: 10.1038/nrneurol.2013.23. No abstract available.

The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease.

Zeng L, Tallaksen-Greene SJ, Wang B, Albin RL, Paulson HL.

J Huntingtons Dis. 2013;2(2):201-15. doi: 10.3233/JHD-130058.

Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice.

Renoir T, Pang TY, Mo C, Chan G, Chevarin C, Lanfumey L, Hannan AJ.

J Physiol. 2013 Jan 1;591(1):41-55. doi: 10.1113/jphysiol.2012.239798.

Neurovascular abnormalities in humans and mice with Huntington's disease.

Lin CY, Hsu YH, Lin MH, Yang TH, Chen HM, Chen YC, Hsiao HY, Chen CC, Chern Y, Chang C.

Exp Neurol. 2013 Dec;250:20-30. doi: 10.1016/j.expneurol.2013.08.019.

Genetic modifiers in Huntington's disease: fiction or fact?

Arning L, Epplen JT.

Neurogenetics. 2013 Nov;14(3-4):171-2. doi: 10.1007/s10048-013-0365-x. No abstract available.

Growth Hormone Deteriorates the Functional Outcome in an Experimental Model of Huntington's Disease Induced by 3-Nitropionic Acid.

Park JE, Lee ST, Im WS, Kim M.

J Mov Disord. 2013 Oct;6(2):28-33. doi: 10.14802/jmd.13007.

A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.

Huntington Study Group HART Investigators..

Mov Disord. 2013 Sep;28(10):1407-15. doi: 10.1002/mds.25362.